Real-World Use of Iptacopan in Treatment-Resistant Crescentic IgAN (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #TH-PO0522; Pres time: Oct 22, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "The patient was initially treated with high dose corticosteroids followed by budesonide without meaningful improvement. Rituximab, mycophenolate mofetil and tacrolimus were subsequently attempted with minimal benefit. Cyclophosphamide was discussed but declined because of fertility concerns...Iptacopan selectively inhibits factor B, blocking amplification of the alternative complement cascade. This case highlights the potential role of complement targeted therapy in treatment resistant crescentic IgAN, particularly in patients with prominent C3 deposition and failure of conventional immunosuppressive therapy."
Clinical • Real-world • Real-world evidence • Fibrosis • Glomerulonephritis • IgA Nephropathy • Immunology • Lupus Nephritis • Nephrology • Renal Disease
|
|
William M. Parkinson; Tareq Issa Nassar; Swetha Rani Kanduri
|